8-K
Elanco Animal Health Inc (ELAN)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 22, 2021
Elanco
Animal Health Incorporated
(Exact name of registrant as specified in its charter)
| Indiana | 001-38661 | 82-5497352 |
|---|---|---|
| (State<br> or other jurisdiction of<br> <br>incorporation) | (Commission<br><br> File Number) | (I.R.S.<br> Employer<br> <br>Identification<br> No.) |
| 2500 Innovation Way<br><br> <br>Greenfield, Indiana<br> <br>(Address of principal executive offices) | 46140<br> <br>(Zip<br> Code) | |
| --- | --- |
Registrant’s telephone number, including area code:
(877
)
352-6261
Not Applicable
(Former Name or Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications<br>pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant<br>to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communications<br>pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communications<br>pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, no par value | ELAN | New York Stock Exchange |
| 5.00% Tangible Equity Units | ELAT | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events |
|---|
On February 22, 2021, Elanco Animal Health Incorporated issued a press release announcing that a member of its Executive Committee, Michael-Bryant Hicks, Executive Vice President, General Counsel and Corporate Secretary, will leave Elanco on March 2, 2021. The press release is attached hereto as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits |
|---|
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release issued by Elanco Animal Health Incorporated,<br>dated February 22, 2021. |
| 104.1 | Cover Page Interactive Data File (embedded within the Inline<br> XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Elanco Animal Health Incorporated | ||
|---|---|---|
| Date: February 22, 2021 | By: | /s/ Todd Young |
| *Name:*Todd Young | ||
| Title: Executive Vice President and Chief Financial Officer |
Exhibit 99.1
| Elanco Animal Health<br><br> <br>****<br><br> <br>2500 Innovation Way<br><br> <br><br><br> <br>Greenfield, IN 46140 |
|---|
FOR IMMEDIATE RELEASE
Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com
Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com
Elanco General Counsel Michael-BryantHicks to Depart After Successful Company Stand-Up and Acquisition Completion
GREENFIELD, Ind. (February 22, 2021) Elanco Animal Health Incorporated (NYSE: ELAN) today announced the departure of executive vice president Michael-Bryant Hicks (“Hicks”). He joined Elanco in 2018 as General Counsel and Corporate Secretary to prepare the company for IPO, build the Legal department structure for the stand-alone company, and complete the successful acquisition of Bayer Animal Health.
“I am grateful to Hicks for his contributions to Elanco, providing the legal expertise we needed to successfully transform into a stand-alone animal health company while completing the industry’s biggest acquisition,” said Jeff Simmons, president and CEO at Elanco. “His skill set is unique, and I fully support his aspiration to lead other companies through the same type of dynamic transformation Elanco’s undertaken.”
Hicks will depart Elanco on March 2 and the process to backfill the role is currently underway.
“The last three years at Elanco have been some of the most rewarding in my career, with the opportunity to work alongside talented teammates and make significant contributions in the company’s formative years,” said Michael-Bryant Hicks. “I’m looking forward to taking this experience forward to help others navigate these same types of exciting opportunities.”
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.